Please login to the form below

Not currently logged in
Email:
Password:

OncoVex

This page shows the latest OncoVex news and features for those working in and with pharma, biotech and healthcare.

AZ signs yet another cancer immunotherapy deal

AZ signs yet another cancer immunotherapy deal

The most advanced is Amgen's OncoVex (talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer

Latest news

  • Amgen says viral melanoma therapy clears phase III trial Amgen says viral melanoma therapy clears phase III trial

    OncoVex demonstrates durable response in skin cancer patients. A novel therapy for skin cancer which makes use of the cell-killing activity of a virus has shown efficacy in a phase ... The melanoma immunotherapeutic - talimogene laherparepvec (also known

  • Disease focus: Melanoma

    nilotinib. In development. Vaccines. OncoVEX GM-CSF. In development. Vaccines. MAGE-A3 ASCI.

  • Amgen to buy BioVex

    BioVex's portfolio includes OncoVex (GM-CSF) – an investigational vaccine to treat melanoma and head and neck cancer. ... Philip Astley-Sparke, CEO, BioVex, also praised the agreement: "Amgen is ideally positioned to leverage the potential of OncoVEX

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics